Ono Pharmaceutical is putting AI agents in front of the scientists who run its earliest-stage research. Under a collaboration announced on July 28, 2026, the Osaka drugmaker will deploy Biomni Lab, the agentic research platform built by South San Francisco applied-AI lab Phylo, across its drug discovery organization. What the platform is meant to absorb, according to the announcement, is the full span of a discovery scientist’s computational day: synthesizing a program’s experimental history…